Generic Name and Formulations:
Dyphylline 200mg, 400mg; scored tabs.
Indications for LUFYLLIN:
For relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.
Individualize. Usual dose: up to 15mg/kg every 6 hours. Renal impairment: adjust dose.
Not for primary treatment of acute attack. Severe cardiac disease. Hypertension. Hyperthyroidism. Acute myocardial injury. Peptic ulcer. Pregnancy (Cat.C). Nursing mothers.
Toxicity with concomitant sympathomimetics. Potentiated by probenecid.
GI upset, epigastric pain, hematemesis, headache, irritability, restlessness, insomnia, hyperexcitability, agitation, muscle twitching, generalized clonic and tonic convulsions, palpitation, tachycardia, extrasystoles, flushing, hypotension, circulatory failure, ventricular arrhythmias, tachypnea, gross and microscopic hematuria, diuresis, hyperglycemia, inappropriate ADH syndrome.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|